Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Assets (2020 - 2025)

HCW Biologics (HCWB) has disclosed Assets for 6 consecutive years, with $25.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Assets fell 4.18% year-over-year to $25.4 million, compared with a TTM value of $25.4 million through Sep 2025, down 4.18%, and an annual FY2024 reading of $30.2 million, up 6.04% over the prior year.
  • Assets was $25.4 million for Q3 2025 at HCW Biologics, down from $28.9 million in the prior quarter.
  • Across five years, Assets topped out at $56.4 million in Q3 2021 and bottomed at $13.0 million in Q2 2021.
  • Average Assets over 5 years is $36.7 million, with a median of $33.0 million recorded in 2023.
  • The sharpest move saw Assets soared 263.75% in 2022, then plummeted 39.09% in 2023.
  • Year by year, Assets stood at $53.5 million in 2021, then fell by 12.53% to $46.8 million in 2022, then tumbled by 39.09% to $28.5 million in 2023, then grew by 6.04% to $30.2 million in 2024, then dropped by 15.85% to $25.4 million in 2025.
  • Business Quant data shows Assets for HCWB at $25.4 million in Q3 2025, $28.9 million in Q2 2025, and $26.3 million in Q1 2025.